drugset / Trial / NCT02199873

Safety, Tolerability and Pharmacodynamics of BIIX 1 XX in Healthy Young Male Volunteers

NCT02199873 ↗

Phase 1 Completed 24 enrolled Boehringer Ingelheim
RandomizedSingle-groupDouble-blindTreatment

Summary

The objective of the present study is to obtain information about the safety and tolerability of BIIX 1 XX, to determine the pharmacologically active dose (range) by performing a methacholine challenge test and to obtain preliminary pharmacokinetic data

Timeline

Start
1998-06
Primary completion
1998-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BIIX 1 XX Unknown 5 ug Inhaled
Subject BIIX 1 XX Unknown 800 ug Inhaled

Indications

No indication recorded.